Navigation Links
STAAR Surgical Receives Japanese Clearance for the KS-Ni Preloaded IOL Injector System
Date:6/17/2009

MONROVIA, Calif., June 17 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the approval of the KS-Ni Preloaded Silicone Intraocular Lens (IOL) injector system by Japanese regulatory authorities.

The KS-Ni Preloaded Silicone IOL Injector System allows the surgeon to deliver STAAR Japan's blue-blocker silicone IOL through an incision size of 2.6 mm as compared to the current 3.2 mm incision size. A smaller incision will likely induce less astigmatism and allows for quicker healing. The KS-Ni Preloaded System also provides for fewer steps in the delivery process of the IOL making the system more user friendly for nurses and surgeons.

"The approval of the KS-Ni Preloaded IOL Injector continues to highlight the rapid fire launch of products that leverage STAAR Japan's expertise in the area of preloaded delivery systems for foldable IOLs," said Barry G. Caldwell, President and CEO of STAAR Surgical. "During the past week STAAR has received three different product regulatory approvals in the U.S., Europe and now Japan which illustrates the results of our continuous improvement efforts by our quality and regulatory teams."

The KS-Ni Preloaded Injector System also offers benefits to the Company as there are more than one third fewer components making the system easier to assemble and less costly to manufacture. The Company is evaluating the opportunity to expand the system to other key markets.

About STAAR Surgical

STAAR Surgical is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 50 countries. Collamer(R) is the brand name for STAAR's proprietary collagen copolymer lens material. More information is available at www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: projections of any financial items; the plans, strategies, and objectives of management for future operations or prospects for achieving such plans; the success of the KS-Ni Injector System or other products, our future performance; statements of belief; and any statements of assumptions underlying any of the foregoing.

These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the need to satisfy the judgment in the Parallax case or post an appeal bond and the resulting effect on our liquidity, our limited capital resources and limited access to financing, the need to defend other litigation similar to the Parallax case and to satisfy judgment in the event of an adverse ruling in that case, for which we have taken no reserve, the effect the global recession may have on sales of products, especially products such as the ICL used in non-reimbursed elective procedures, the challenge of managing our foreign subsidiaries, the risk that our newly introduced products will not draw significant new business to our IOL product line, our ability to resolve FDA concerns over the clinical study for the Toric ICL and to overcome negative publicity resulting from warning letters and other correspondence from the FDA Office of Compliance, the willingness of surgeons and patients to adopt a new product and procedure, and the potential effect of recent negative publicity about LASIK on the demand for refractive surgery in general in the U.S.

    CONTACT:  Investors                       Media
              EVC Group                       EVC Group
              Douglas Sherk, 415-896-6820     Christopher Gale 646-201-5431
              Michael Pollock, 415-896-5862


'/>"/>
SOURCE STAAR Surgical Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. STAAR Surgical Reports Operational Progress
2. STAAR Surgical Announces Third Quarter 2007 Earnings Release Date and Conference Call
3. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
4. STAAR Surgical Reports Third Quarter Results
5. Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical
6. STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference
7. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
8. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show
11. STAAR Surgical Reports Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Guide to FDA and EU Medical ... matter on which side of the Atlantic devicemakers do business, this fully updated and ... follow. , In addition to the full text of the FDA’s regulations in 21 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... a one-day corporate governance program for mid-market executives as a kick-off to the ... held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, followed by ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
(Date:6/27/2017)... , ... June 27, 2017 , ... DrugDev ... is whether they can trust the sponsor to pay them correctly and on time. ... and CROs establish payment strategies that encourage sites to work on their studies. , ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
Breaking Medicine Technology: